Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection
Status:
Recruiting
Trial end date:
2023-01-22
Target enrollment:
Participant gender:
Summary
Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may
cause different diseases. In most cases, EBV infection is asymptomatic because of a highly
effective host immune response. Some individuals develop infectious mononucleosis (a
self-limiting lymphoproliferative disorder in adolescents and young adults that is considered
to be the primary infection), while others develop chronic fatigue syndrome, EBV-associated
lymphoid, or epithelial malignancies.
Today, there is no available treatment to treat and destroy EBV. The treatment is essentially
symptomatic (treatment of the symptoms and not of the virus itself) with analgesics for pain
for example.
The studied drugs are 2LEBV® and 2LXFS®, from Labo'Life company, and the treatment schema is
the same for the two drugs: it consists in taking the content of one capsule per day,
sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is
taken, capsule 1 of the next blister should be taken on the next day to continue the
treatment.
The duration of treatment will be of 6 months of continuous intake of the content of 1
capsule/day.
The aim of this study is to provide additional information on effectiveness on the 2LEBV® and
2LXFS®in the treatment of EBV chronic and acute infections, and in particular to demonstrate
their effectiveness versus placebo in the reduction of asthenia and other symptoms in EBV
infection.